Loading... Please wait...
Categories
New Products
-
$350.00 -
$95.00 -
$175.00 -
$550.00 -
$790.00
Our Newsletter
- Home
- Disease Area
- Neuroscience
- SYN115 | Adenosine A(2a) receptor antagonist
- Home
- Molecular Target
- GPCR
- SYN115 | Adenosine A(2a) receptor antagonist
Product Description
SYN115 (Tozadenant) is a orally-available, benzothiazole-based, antagonist of the Adenosine A2A receptor for the treatment of Parkinson's disease and other CNS-related conditions. SYN115 is being pursued as a monotherapy as well as in combination with L-dopamine and is being studied for its potential neuroprotective effects. [1]
Animal studies with SYN115 support beliefs that A2A antagonists reduce Parkinson's symptoms by reducing the inhibitory output of the basal ganglia indirect pathway. Using Cerebral Blood Flow (CBF) as a pharmacodynamic parameter, studies have shown that SYN115 induces a significant decrease in thalamic CBF, consistent with the deactivation of the indirect pathway. [2]
Technical information:
| Chemical Formula: | C19H26N4O4S | |
| CAS #: | 870070-55-6 | |
| Molecular Weight: | 406.5 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide | |
| Solubility: | Up to 50 mM in DMSO | |
| Synonyms: | SYN115, SYN-115 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Biotie Therapies website (2013-04-24) |
| 2. | Black et al., Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease. Black et al., J. Neurosci. 2010, 30(48), 16284-16292. Pubmed ID: 21123574 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
